University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 4 of 16
Vasoactive Drugs in Intensive Care Unit
NCT02118467
Islet Transplantation in Patients With "Brittle" Type I Diabetes
NCT01630850
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
NCT01280825
Islet Transplantation in Type 1 Diabetic Kidney Allograft
NCT01241864
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
NCT01416714
Explanted Lung Tissues With Pulmonary Fibrosis
NCT00515567
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
NCT00470327
Genetics of Cardiovascular and Neuromuscular Disease
NCT00138931
Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use
NCT06682468
The Sinonasal Microbiome
NCT06822725
Communication Bridge Pilot Study
NCT06211374
Virtual Diabetes Group Visits Across Health Systems
NCT06094491
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
NCT06110195
Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors
NCT05796752
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
NCT05624528
Physical Activity Intervention for Black Women With Asthma
NCT05726487
Basic Experimental Study of Hippocampal Memory Functions
NCT05945628
Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women
NCT05534932
Voice-Activated Technology to Improve Mobility in Multimorbid, Frail, Homebound Older Adults (EngAGE)
NCT05337514
Collaborative Urological Prosthetics Investigation Directive Research Group
NCT05100654
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
NCT05019976
Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)
NCT04775004
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
NCT04948203
Technology-Supported Treatment of Sleep Apnea in Prediabetes
NCT04225507
Using Technology to Address Disparities and Promote Healthcare Equity in Type 1 Diabetes Registry
NCT06899984
Alterations of the Microbiome During Critical Illness With Short and Long Term Clinical Outcomes
NCT04552834
Biomarkers of CASH
NCT04467489
Long Term Outcomes of Patients With COVID-19
NCT04360538
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
NCT03844815
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
NCT04108624
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
NCT03995147
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
NCT04157322
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03729804
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
NCT03500445
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
NCT03674814
An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury
NCT03590028
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
NCT03360890
Behavioral Chronotype: Impact on Sleep and Metabolism
NCT03647306
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
NCT03283137
Supportive Release Center Study
NCT03616990
Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy
NCT03238976
Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer
NCT03223155
Study to Determine if Patients Exposed to General Anesthesia Significant Numbers of Times Would Increase the Risk for Intraoperative Awareness.
NCT05857618
Wearable Gait Sensors
NCT06628934
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
NCT02841748
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
NCT02788981
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
NCT02743819
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
NCT02659293
Random Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy
NCT04120805
Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation
NCT02647723
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Chicago pipeline card: 796 registered trials from official public datasets.Report a data error.